Evidence map›Paper›PMID 40370562›Full record

ArticleActa pharmaceutica Sinica. B2025

Nitazoxanide protects against heart failure with preserved ejection and metabolic syndrome induced by high-fat diet (HFD) plus L-NAME "two-hit" in mice.

Jiahui Chen, Liping Zhang, Ting Xie, Xiao Zhang, Congcong Pan, Fangli Sun, Wenfeng Li, Zhijie Sun, Deli Dong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jiahui ChenDepartment of Pharmacology, China Pharmaceutical University, Nanjing 211198, China.
Liping ZhangDepartment of Pharmacology, China Pharmaceutical University, Nanjing 211198, China.
Ting XieDepartment of Pharmacology, China Pharmaceutical University, Nanjing 211198, China.
Xiao ZhangDepartment of Pharmacology, China Pharmaceutical University, Nanjing 211198, China.
Congcong PanDepartment of Pharmacology, China Pharmaceutical University, Nanjing 211198, China.
Fangli SunDepartment of Pharmacology, China Pharmaceutical University, Nanjing 211198, China.
Wenfeng LiDepartment of Pharmacology, China Pharmaceutical University, Nanjing 211198, China.
Zhijie SunDepartment of Pharmacology, China Pharmaceutical University, Nanjing 211198, China.
Deli DongDepartment of Pharmacology, China Pharmaceutical University, Nanjing 211198, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clinical antiprotozoal drug nitazoxanide has been demonstrated to improve the experimental diabetes mellitus, lipid metabolism disorders, atherosclerosis and inhibit inflammation. Since the pathogenesis of heart failure with preserved ejection (HFpEF) is multifactorial and closely associated with the aforementioned diseases, we aim to study the effect of nitazoxanide on high-fat diet (HFD) plus L-NAME (

Indexed as

Heart fibrosisHeart hypertrophyHepatic steatosisHFpEFMetabolic syndromeNitazoxanideTizoxanide

Identifiers

PMID40370562
PMCPMC12069241

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.